Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fentanyl continuous perfusion vs on-demand morphine for refractory dyspnea in acute decompensated heart failure
2024-520025-36-00Phase 4Authorised
- Sponsor
- Fundació Assistencial de Mútua de Terrassa
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of fentanyl in heart failure (HF) (2 arms), sponsored by Fundació Assistencial de Mútua de Terrassa. Primary endpoint: Reduction in average daily dyspnea intensity (EVN and VAS). Planned start Jan 2025; status: authorised.
02
Drugs
fentanyl
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2024-520025-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520025-36-00.